Year: 2025
Type: article
Abstract: Migraine is a highly prevalent neurological disorder that imposes substantial personal and societal burdens.Traditional therapies, including triptans and repurposed preventive agents, have long provided benefit but are constrained by incomplete efficacy, recurrence, and tolerability issues.Recent advances in neurobiology have driven the development of migraine-specific therapies that align more closely with underlying mechanisms.Ditans, selective 5-hydroxytryptamine receptor1F receptor agonists, offer acute relief without vasoconstriction and expand options for patients with vascular comorbidities.Gepants, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, represent a versatile class effective in both acute and preventive therapy, with favorable safety profiles even in high-risk populations.Monoclonal antibodies targeting CGRP or its receptor have redefined preventive care, demonstrating durable efficacy with infrequent dosing and establishing new standards in long-term management.Combination strategies, including triptannon-steroidal anti-inflammatory drugs (NSAID) formulations and botulinum toxin injections, provide further benefit in refractory cases.Emerging approaches-such as pituitary adenylate cyclase-activating polypeptide (PACAP) antagonists, novel delivery systems, and neuromodulation technologies-highlight the continuing expansion of therapeutic horizons.The integration of biomarkers and precision-medicine approaches promises to refine patient selection and optimize individualized treatment strategies.In conclusion, the evolution of migraine therapeutics reflects a shift from nonspecific symptom relief toward targeted, mechanism-based interventions.By addressing both acute and preventive needs, these innovations expand clinical possibilities, reduce disease burden, and move migraine care toward a future defined by personalized, biologically informed treatment.
Source: NeuroTrials
Authors: Yoon-Kyung Chang, Tae-Jin Song
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4416838917